title: Economic assessment of thrombocytopenia: CATCH Registry.
abstract: Thrombocytopenia is associated with increased patient risk. However, the costs of this complication are not well defined. This study assessed the impact of thrombocytopenia on in-hospital costs using results from CATCH, an observational study that examined 1988 consecutive patients receiving prolonged heparin therapy (> or =96 h). Thrombocytopenia was defined as: (group 1) an absolute reduction in platelet count to <150 x 10(9)/L; (group 2) a relative reduction in platelet count of >50% from admission levels; or (group 3) both criteria. We found that the development of thrombocytopenia was associated with significantly higher total in-hospital costs for all groups: (group 1) (difference, $8,222; 95% CI, $5,020-$11,425; P<.001); (group 2) (difference, $15,429; 95% CI, $7,472-$23,385; P<.001); and (group 3) (difference, $27,077; 95% CI, $22,901-$31,252; P<.001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences.
authors.affiliation: Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. eric.eisenstein@duke.edu
authors.forename: Eric L
authors.initials: EL
authors.lastname: Eisenstein
authors.forename: Emily F
authors.initials: EF
authors.lastname: Honeycutt
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Anstrom
authors.forename: Richard C
authors.initials: RC
authors.lastname: Becker
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Granger
authors.forename: Sunil V
authors.initials: SV
authors.lastname: Rao
authors.forename: Marc E
authors.initials: ME
authors.lastname: Jolicoeur
authors.forename: E Magnus
authors.initials: EM
authors.lastname: Ohman
mesh_terms: D000368:Aged; D001803:Blood Transfusion / Q000191:economics / Q000706:statistics & numerical data; D003365:Costs and Cost Analysis; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006493:Heparin / Q000009:adverse effects; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D007902:Length of Stay / Q000191:economics / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D012042:Registries; D013921:Thrombocytopenia / Q000139:chemically induced / Q000191:economics* / Q000628:therapy; D014481:United States
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin